Gaëtan Devos

Dr. Gaëtan Devos

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2021 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
GDGaëtan Devos
Gaëtan Devos
Wout DevliesWout Devlies
Wout Devlies
GMGert De Meerleer
Gert De Meerleer
MBMarcella Baldewijns
Marcella Baldewijns
TGThomas Gevaert
Thomas Gevaert
Steven JoniauSteven Joniau
Steven Joniau

13 August 2020 in Cancers
Verified
Journal Article
Open access
PDF file
GDGaëtan Devos
Gaëtan Devos
CBCharlien Berghen
Charlien Berghen
HEHenri Van Eecke
Henri Van Eecke
ASArthur Vander Stichele
Arthur Vander Stichele
HPHendrik Paul Van Poppel
Hendrik Paul Van Poppel
Steven JoniauSteven Joniau
Steven Joniau
Several retrospective and a few prospective studies have shown that metastasis-directed therapy (MDT) could delay clinical progression and postpone the initiation of systemic treatment in oligorecurrent prostate cancer (PCa) patients. However, these endpoints are strongly influenced by variables such as concomitant use of androgen deprivation therapy (ADT) and follow-up imaging protocols. The aim of this manuscript was to assess palliative ADT- and metastatic castration-resistant prostate cancer (mCRPC)-free survival as long-term oncological outcomes in oligorecurrent PCa treated by MDT. We retrospectively identified consecutive post-prostatectomy oligorecurrent PCa patients treated by MDT (salvage lymphadenectomy, radiotherapy, or metastasectomy) at our tertiary referral center. Patients were eligible for inclusion if they developed recurrence following radical prostatectomy, had ≤5 metastatic lesions on imaging and had a serum testosterone >50 ng/dL or a testosterone suppression therapy-free interval of >2 years prior to the first MDT as an assumption of recovered serum testosterone (if no testosterone measurement available). Patients with castration-resistant or synchronous oligometastatic PCa at the time of first MDT were excluded. Repeated MDTs were allowed, as well as a period of concomitant ADT. Kaplan–Meier analyses were performed to assess palliative ADT-free and mCRPC-free survival. We identified 191 eligible patients who underwent MDT. Median follow-up from first MDT until last follow-up or death was 45 months (IQR 27–70; mean 51 months). Estimated median palliative-ADT free survival was 66 months (95% CI 58–164) and estimated median mCRPC-free survival was not reached (mean 117 months, 95% CI 103–132). In total, 314 MDTs were performed and 25 patients (13%) received ≥3 MDTs. This study demonstrated that (repeated) MDT is feasible and holds promise in terms of palliative ADT-free and mCRPC-free survival for patients with oligorecurrent PCa. However, these findings should be confirmed in prospective randomized controlled trials.

22 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Wout DevliesWout Devlies
Wout Devlies
FHFlorian Handle
Florian Handle
GDGaëtan Devos
Gaëtan Devos
Steven JoniauSteven Joniau
Steven Joniau
FCFrank Claessens
Frank Claessens
Prostate cancer is an androgen-driven tumor. Different prostate cancer therapies consequently focus on blocking the androgen receptor pathway. Clinical studies reported tumor resistance mechanisms by reactivating and bypassing the androgen pathway. Preclinical models allowed the identification, confirmation, and thorough study of these pathways. This review looks into the current and future role of preclinical models to understand resistance to androgen receptor-targeted therapies. Increasing knowledge on this resistance will greatly improve insights into tumor pathophysiology and future treatment strategies in prostate cancer.

17 November 2020 in Cells
Verified
Journal Article
Open access
PDF file
Wout DevliesWout Devlies
Wout Devlies
Markus EcksteinMarkus Eckstein
Markus Eckstein
ALESSIA CIMADAMOREALESSIA CIMADAMORE
ALESSIA CIMADAMORE
GDGaëtan Devos
Gaëtan Devos
LMLisa Moris
Lisa Moris
TGThomas Gevaert
Thomas Gevaert
The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.

13 September 2024 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
NBNiloefar Ahmadi Bidakhvidi
Niloefar Ahmadi Bidakhvidi
TGThomas Gevaert
Thomas Gevaert
MSMaxim De Schepper
Maxim De Schepper
MBMarcella Baldewijns
Marcella Baldewijns
EHEnrique Havinga
Enrique Havinga
Karolien GoffinKarolien Goffin
Karolien Goffin

12 February 2021 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
GDGaëtan Devos
Gaëtan Devos
BVBram Vansevenant
Bram Vansevenant
GMGert De Meerleer
Gert De Meerleer
ACAndries Clinckaert
Andries Clinckaert
Wout DevliesWout Devlies
Wout Devlies
SJSteven Joniau
Steven Joniau